FY2025 EPS Estimates for CureVac Raised by Leerink Partnrs

CureVac (NASDAQ:CVAC) – Analysts at Leerink Partnrs boosted their FY2025 EPS estimates for CureVac in a note issued to investors on Wednesday, January 22nd. Leerink Partnrs analyst M. Foroohar now anticipates that the company will post earnings per share of ($0.54) for the year, up from their previous forecast of ($0.60). The consensus estimate for CureVac’s current full-year earnings is $0.72 per share.

CureVac Price Performance

Shares of NASDAQ:CVAC opened at $3.96 on Friday. The company’s fifty day moving average is $3.31 and its two-hundred day moving average is $3.19. The company has a market cap of $886.56 million, a P/E ratio of 7.20 and a beta of 2.50. CureVac has a 12-month low of $2.21 and a 12-month high of $5.28. The company has a quick ratio of 6.19, a current ratio of 6.20 and a debt-to-equity ratio of 0.05.

Hedge Funds Weigh In On CureVac

Several institutional investors and hedge funds have recently bought and sold shares of CVAC. Private Advisor Group LLC acquired a new position in shares of CureVac in the 3rd quarter valued at about $30,000. International Assets Investment Management LLC purchased a new stake in CureVac in the 3rd quarter worth approximately $35,000. Integrated Wealth Concepts LLC purchased a new stake in CureVac in the 3rd quarter worth approximately $35,000. Bank of New York Mellon Corp purchased a new position in shares of CureVac during the 2nd quarter valued at $54,000. Finally, Barclays PLC acquired a new position in shares of CureVac in the third quarter worth $67,000. Hedge funds and other institutional investors own 17.26% of the company’s stock.

About CureVac

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.